Published on 1 Dec 2022 on Simply Wall St. via Yahoo Finance

Investors in EyePoint Pharmaceuticals (NASDAQ:EYPT) have unfortunately lost 79% over the last year

It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to avoid truly shocking capital losses. It must have been painful to be a EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholder over the last year, since the stock price plummeted 79% in that time. While some investors are willing to stomach this sort of loss, they are usually professionals who spread their bets thinly. Notably, shareholders had a tough run over the longer term, too, with a drop of 79% in the last three years. Shareholders have had an even rougher run lately, with the share price down 68% in the last 90 days. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

View our latest analysis for EyePoint Pharmaceuticals